DVT & Pulmonary Embolism
ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the...
AUSTIN, TEX. – Although the study matched patients by demographic factors, researchers did not adjust the analysis for risk factors or confounders...
News from the FDA/CDC
The latest approval is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 patients.
From the Journals
Readmission for venous thromboembolism in patients with inflammatory bowel diseases most often occurs within 60 days of discharge.
AMSTERDAM – VTE risk modeling is available for patients with solid tumors, but a similar prognostic tool for leukemia patients has been missing....
SAN DIEGO – Real-world studies comparing the GI bleeding rates among different non–vitamin K anticoagulants have been limited.
NEW ORLEANS – National Inpatient Sample data showed that during 2004-2015 hospitalized U.S. patients with a PE diagnosis jumped by 80%.
NEW ORLEANS – Dropping aspirin but keeping anticoagulation with apixaban and antiplatelet clopidogrel was effective and associated with less...
SEATTLE – Two studies detail the risk factors of first-time venous thromboembolism and heightened incidence of repeat VTE in patients with HIV.